CeleCor Therapeutics

CeleCor Therapeutics is a small biotechnology company based in Del Mar, California, with a team of three employees. The company focuses on developing life-saving pre-hospital therapies for heart attack patients. CeleCor Therapeutics aims to improve patient outcomes by addressing the critical need for early treatment in the pre-hospital phase of heart attack care. Their lead product, zalunfiban, is a promising medication designed to be administered as a single subcutaneous injection to patients experiencing a heart attack before they reach the hospital. Zalunfiban is being developed as a prompt, potent, and predictable treatment for ST-segment elevation myocardial infarction (STEMI). The company is currently conducting the CeleBrate trial, a large-scale, international, multicenter study designed to evaluate the safety and efficacy of zalunfiban in the pre-hospital setting. For more information about CeleCor Therapeutics and its innovative therapies, visit www.celecor.com.